Advertisement

Topics

Nonalcoholicsteatohepatitis NASH Pipeline Analysis [Report Updated: 16072015] Prices from USD $3600

12:56 EDT 18 Aug 2017 | BioPortfolio Report Blog

NonalcoholicsteatohepatitisNASHPipelineAnalysisgivescomprehensiveinsightonthevariousdrugsbeingdevelopedforthetreatmentofNASH.ThereportcoversallthedrugsbeingdevelopedinvariousphasesDiscovery,PreclinicalClinicaldevelopment.Thepipelinefocusesonnovelmedicinescoveringsmallmolecules,monoclonalantibodies,RecombinantproteinsandRNAbasedtherapeutics,butexcludesOfflabel,symptomreliefdrugs,genericcombinations.ThereportalsocovershottargetsinresearchforNASHtreatmentsanddiseaseprogressionbiomarkers.
ThisreportenablesPharmaceutical/Biotechcompanies,Academicinstitutes,Individualresearchers,Investors,Medicaltechnologycompanies,Serviceprovidersandotherassociatedstakeholderstoidentifyandanalyzetheavailablelicensing/collaborativecommercialopportunitiesintheNonalcoholicsteatohepatitisNASHDrugmarket.ThereportalsoprovidesstrategicinsightsonmedicinesthatarelikelytohaveanimpactonfutureNASHtreatmentspace.
NASHisassociatedwithfattyliver,hepaticinflammation,hepatocyteinjuryandfibrogenesisandmayworsenintofibrosisorcirrhosis,liverfailureandrarelyintolivercancer.Currently,therearenoapproveddrugsforNASHbyU.S.FoodandDrugAdministrationFDAandthereahighunmetclinicalneed.NASH,ifuntreatedcanprogresstoliverdestroyingcirrhosisandpotentiallycancer.MajorityoftheNASHpipelinedrugsarefromspecialisedsmalltomidpharmaceuticalbiotechcompanies.AssomeofthecandidatesarenearingkeyRDmilestones,thereisahugecompetitionamonglargepharmaceuticalandbiotechcompaniestoacquiretheseassets.Gilead'sacquisitionofPhenexFXRprogramBoehringer'sacquisitionofNASHclinicalassetfromPharmaxissupportsthistrend.DiagnosisofNASHstillrequireshistologicalconfirmationandthereisagreatdemandforspecificnoninvasivediagnosisfordistinguishingNASHfromotherliverdiseases.Therefore,thereisaneedtodevelopbetterdiagnosticandtherapeuticstrategiesforpatientswithNASH.
ThereisatremendousopportunityforupcomingtherapiesspecifictoNASHsuchasMAbs,RNAbasedtherapiesRecombinantproteins.ThesemodalitiesmayprovideAntifibrosis,Antiinflammatoryandmetabolicbenefits.

Original Article: Nonalcoholicsteatohepatitis NASH Pipeline Analysis [Report Updated: 16072015] Prices from USD $3600

NEXT ARTICLE

More From BioPortfolio on "Nonalcoholicsteatohepatitis NASH Pipeline Analysis [Report Updated: 16072015] Prices from USD $3600"

Advertisement
Quick Search
Advertisement
Advertisement